Rosário Serrão

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study

Catherine Orrell, Debbie Hagins, Elena Belonosova et al. · The Lancet HIV · 2017 · 118 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Non-AIDS-related comorbidities in people living with HIV-1 aged 50 years and older: The AGING POSITIVE study

Rosário Serrão, Carmela Piñero, Jorge Julián Vélez Upegui et al. · International Journal of Infectious Diseases · 2018 · 83 citations · Full text

Education, Geriatric Medicine, Health Sciences +17

Peginterferon alfa-2a Plus Ribavirin for HIV-HCV Genotype 1 Coinfected Patients: A Randomized International Trial

M. Rodríguez‐Torres, Jihad Slim, Laveeza Bhatti et al. · HIV Clinical Trials · 2012 · 65 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

Pedro Cahn, Richard Kaplan, Paul E. Sax et al. · The Lancet HIV · 2017 · 35 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15